Company
LON:GDR
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms.
240 stories · page 3 of 12
Hardware & electrical equipment
The tie-up with Mountain Horse Solutions helps overcome the “challenging and time consuming” process of contracting with the American government, the company said
The updated advice follows work carried out by researchers Manchester University NHS Foundation Trust and Liverpool Women's Hospital using the company’s assay designed specifically to detect AHL
A glance at some of the day's highlights from the Proactive Investors newswire
The 96 SARS-CoV-2 technology is said to be ideally suited for use on Beckman Coulter’s high throughput robotic Biomek i7 instrument
Here we take a closer look at Genedrive PLC (LON:GDR)
Archive
A look at some of the major movers in London on Thursday
The agreement allows the American biomedical company to sell and distribute genedrive's COVID-19 PCR test
The kit is designed to target both the E and N genes of SARS-CoV-2, said Genedrive.
The company has told the US Food & Drug Administration that it intends to import and distribute the product prior to emergency use authorisation
The company said it was now working with the study team as well as commercial partner, Inspiration Healthcare, ahead of the commercial roll-out
The work was carried out by Dr Ekta Gupta at the Institute of Liver and Biliary Sciences, New Delhi
"If converted to a sale this would be for low double-digit millions of pounds of revenue and delivered in the first quarter of the new calendar year without the need for prolonged regulatory approvals," added Dr Ian Gilham
The simplicity and speed of the test mean results can be delivered while the patient waits, rather than material having to be shipped and then assessed, which takes at least 24 hours
“South Africa is a key territory for our distributors and this approval will now provide an acceleration of commercial sales activity in the area,” said CEO David Budd
Initial testing took place using Beckman Coulter Life Sciences' chemistry on respiratory swabs in conjunction with gendrive’s 96 SARS-CoV-2 equipment
Archive
Britain's benchmark of leading shares finished the day up around 79 points, or 1.32%, to 6,105
We look at the sector's success stories and assess what we can expect in the coming months
"The integration of Beckman Coulter Life Sciences' and genedrive's technologies produces a formidable workhorse solution," said Beckman Coulter’s Greg Milosevich.
Laboratory operators in the US have said a lack of capacity has created a backlog of tests that are being processed too slowly to stem the tide of infections
"We remain encouraged by the interest in our Genedrive 96-SARS-CoV-2 test,” said CEO David Budd
